ISIS drugs without partnerships - Phase 2 - Watch in 2013
Now the drugs that we are focused on in terms of 2013-2014 licensing opportunities are drugs that we think are going to be very valuable where the Phase 2 data showing efficacy will be compelling and where we will generate a giant increase in value just as we did with KYNAMRO and those drugs include the five metabolic drugs that we have in development. We discussed three of them Friday. They include CRP, which we are tremendously excited about. They include Factor 11, which we think is going to be a tremendously important drug for which we are finishing the total knee replacement study today and a number of others.
There is another drug that's apoC-III, where we are very confident this drug is going to work, and we think it’s targeted to a group of patients who have a severe lipid disorder where the Phase 2 data will be tremendously compelling, and that's an area where we have a lot of experience now thanks to KYNAMRO and other drugs. That drug we may hang on to even longer. We will weigh what sort of trends, what sort of interest we have and what an option might look like for that drug as we develop the Phase 2 package. But certainly that's a drug that we might hang on to even longer.